July 16, 2018 10:30 AM EDT

FDA experts back GSK's new malaria drug; Sangamo's newly minted CTO jumps to biotech upstart

Amber Tong

→ GlaxoSmithKline has turned the final corner in the race to gain an FDA approval for tafenoquine, a new treatment for patients with P. vivax …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA experts back GSK's new malaria drug; Sangamo's newly minted CTO jumps to biotech upstart

Amber Tong

Sign up to read this article for free.

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

FDA ex­perts back GSK's new malar­ia drug; Sang­amo's new­ly mint­ed CTO jumps to biotech up­start

Amber Tong

Sign up to read this article for free.

more like this

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

FDA experts back GSK's new malaria drug; Sangamo's newly minted CTO jumps to biotech upstart

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role